chartexchange

Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue

GlobeNewswire Inc. | Oct 14, 2026 8:29 PM EDT

PARSIPPANY, NJ, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCID: IDXG) today announced that it expects preliminary, unaudited revenue for the third quarter ended September 30, 2026 to range from $10.1 million to $10.4 million.

Read original article